BPC-157: Body Protection Compound
A 15-amino acid peptide derived from human gastric juice, extensively studied for tissue repair.
Quick Reference
| Research Dosage | 250-500mcg per day |
|---|---|
| Frequency | Once or twice daily |
| Administration | Subcutaneous injection |
| Cycle Length | 4-8 weeks typical |
| Reconstitution | 2-3mL bacteriostatic water per 10mg vial |
| Storage | Refrigerate after reconstitution, use within 4-6 weeks |
BPC-157 is a 15-amino acid peptide derived from a protective protein found in human gastric juice. It has become one of the most extensively studied peptides in tissue repair research, with over 100 published studies examining its effects across nearly every tissue type in the body.
The peptide was first isolated and characterised by researchers studying the protective factors in gastric juice that help maintain gut integrity despite constant exposure to acid and digestive enzymes. What they discovered was a remarkably stable peptide with tissue-protective properties extending far beyond the gastrointestinal system.
Research Applications
BPC-157 is primarily studied for its effects on tissue healing and repair. Published research has demonstrated benefits across multiple systems:
Musculoskeletal Tissue
Research has extensively documented BPC-157's effects on connective tissue healing:
- Accelerated healing of tendon injuries including Achilles, rotator cuff, and patellar tendons
- Ligament repair including MCL and ACL injury models
- Muscle tear and strain recovery with reduced fibrosis
- Bone-tendon junction (enthesis) repair
- Reduced inflammation in joint tissues
- Improved collagen organisation and tensile strength
Gastrointestinal System
Given its origin from gastric juice, extensive GI research has been conducted:
- Gastric ulcer protection and accelerated healing
- Intestinal barrier integrity restoration (leaky gut models)
- Inflammatory bowel disease models showing reduced inflammation
- Protection against NSAID-induced gastropathy
- Oesophageal damage repair
- Anastomosis (surgical reconnection) healing enhancement
- Fistula healing
Wound Healing
- Surgical incision recovery with improved tensile strength
- Burn wound healing acceleration
- Skin laceration repair
- Reduced scar tissue formation and improved cosmetic outcomes
- Diabetic wound healing models
Nervous System
- Peripheral nerve regeneration following transection
- Neuroprotective effects in dopaminergic systems
- Protection against neurotoxic agents
- Spinal cord injury models
- Traumatic brain injury research
Vascular System
- Blood vessel repair and formation
- Protection against vascular damage
- Improved blood flow to healing tissues
BPC-157's broad tissue effects are attributed to its influence on angiogenesis (blood vessel formation), collagen synthesis, growth factor modulation, and nitric oxide system interactions. Notably, BPC-157 remains stable in gastric acid, which is highly unusual for peptides and allows for oral administration in gut-related research.
Dosage Information
Standard Research Dosages
Dosages commonly referenced in preclinical and clinical literature range from 250-500mcg daily. Studies have utilised both single daily doses and split doses (twice daily administration).
Dosage Protocols by Application
General tissue repair: 250mcg once or twice daily
Significant injuries: Up to 500mcg twice daily, though research suggests diminishing returns beyond this range
Gastrointestinal applications: 250-500mcg daily, with oral administration sometimes utilised given BPC-157's gastric stability
Administration Sites
Research has demonstrated that BPC-157 is effective both locally and systemically. Studies investigating localised tissue repair have administered injections proximal to the target area (near the injury site), while systemic administration via abdominal subcutaneous injection has also shown effectiveness.
Localised administration may provide faster results for specific injuries, as higher concentrations reach the target tissue. However, systemic effects are well-documented regardless of injection site, meaning abdominal injection is effective for injuries anywhere in the body.
Cycle Duration
Research protocols typically range from 4-8 weeks. Observable improvements are commonly noted within 2-3 weeks for acute injuries. Chronic conditions or older injuries may require extended study periods of 6-8 weeks or longer.
Most protocols include a break period of 2-4 weeks between cycles, though this is standard peptide research methodology rather than being based on specific safety concerns with continuous BPC-157 administration.
Reconstitution Guide
Required Materials
- BPC-157 lyophilised powder (5mg or 10mg vial)
- Bacteriostatic water (water containing 0.9% benzyl alcohol)
- Sterile insulin syringe for reconstitution
- Alcohol swabs for sterile technique
Reconstitution Steps
- Allow the BPC-157 vial to reach room temperature before reconstitution
- Draw the appropriate volume of bacteriostatic water into the syringe:
- For 10mg vial: 2-3mL bacteriostatic water
- For 5mg vial: 1-2mL bacteriostatic water
- Insert the needle into the BPC-157 vial and direct the stream of water down the inside wall of the vial – do not spray directly onto the powder
- Allow the powder to dissolve naturally without shaking. Gentle swirling is acceptable if needed. Complete dissolution typically occurs within a few minutes. The solution should be clear with no visible particles.
- Store reconstituted solution refrigerated at 2-8°C immediately after reconstitution
Concentration Reference Table
| Vial Size | Water Added | Concentration | 250mcg Dose | 500mcg Dose |
|---|---|---|---|---|
| 5mg | 1mL | 5mg/mL | 5 units (0.05mL) | 10 units (0.1mL) |
| 5mg | 2mL | 2.5mg/mL | 10 units (0.1mL) | 20 units (0.2mL) |
| 10mg | 2mL | 5mg/mL | 5 units (0.05mL) | 10 units (0.1mL) |
| 10mg | 3mL | 3.33mg/mL | 7.5 units (0.075mL) | 15 units (0.15mL) |
Storage Guidelines
Lyophilised (Powder) Form
- Stable at room temperature for several weeks without significant degradation
- Refrigeration (2-8°C) extends stability to 12+ months
- Freezing (-20°C) extends stability to 24+ months
- Protect from light and moisture
- Keep vial sealed until ready for reconstitution
Reconstituted Solution
- Must be refrigerated at 2-8°C
- Stable for 4-6 weeks when stored correctly
- Do not freeze after reconstitution – freezing can damage the peptide structure
- Avoid repeated temperature fluctuations
- Use sterile technique when drawing doses to prevent contamination
- If solution becomes cloudy or contains particles, discard and reconstitute a fresh vial
BPC-157 and TB-500 Combination
BPC-157 is frequently studied in combination with TB-500 (Thymosin Beta-4 fragment), commonly referred to as the "Wolverine Stack" or "Healing Stack" in research communities. The rationale for combination research is based on their complementary mechanisms of action:
BPC-157 Mechanism
- Acts primarily through VEGFR2 upregulation and nitric oxide modulation
- Promotes angiogenesis (new blood vessel formation) at the injury site
- Strong localised effects with systemic distribution
- Works on the "repair program" at the cellular level
TB-500 Mechanism
- Acts through actin regulation and cell migration
- Facilitates movement of repair cells to injury sites throughout the body
- More pronounced systemic distribution
- Works on the "delivery system" bringing repair cells where needed
Why They Complement Each Other
BPC-157 establishes blood supply and activates local repair mechanisms, while TB-500 facilitates the migration of repair cells from throughout the body to the injury site. Together, they address multiple phases of the healing cascade simultaneously.
Combination Protocols
Typical combination protocols in literature utilise:
- BPC-157: 250-500mcg daily
- TB-500: 2-2.5mg twice weekly
A pre-blended BPC-157 + TB-500 formulation is available for research convenience, providing accurate ratios and simplified reconstitution.
Frequently Asked Questions
Common questions about BPC-157 research
What is the onset of action for BPC-157?
Published research indicates observable effects within 1-2 weeks for acute injuries. This includes reduced inflammation, pain reduction, and early signs of tissue repair. Chronic conditions or older injuries typically show measurable improvement at 3-4 weeks, with continued improvement over 6-8 weeks of administration.
Can BPC-157 be administered orally?
Yes. BPC-157 demonstrates remarkable stability in gastric acid conditions, unlike most peptides which are rapidly degraded by stomach acid. Oral administration is commonly utilised in gastrointestinal research, including studies on ulcers, inflammatory bowel conditions, and intestinal permeability (leaky gut). Oral dosages referenced in literature are typically higher than injectable doses, ranging from 500mcg to 1mg daily.
Is cycling necessary with BPC-157?
Research protocols typically utilise defined periods of 4-8 weeks followed by washout periods of 2-4 weeks. This approach is standard peptide research methodology that allows for observation of sustained effects and potential tolerance development. No specific safety concerns with continuous BPC-157 administration have been identified in published literature.
Does injection site affect BPC-157 efficacy?
BPC-157 demonstrates systemic effects regardless of administration site – injecting into abdominal fat will still benefit a knee injury, for example. However, research investigating localised tissue repair has shown potentially faster and more pronounced results when administered proximal to the target tissue.
What distinguishes BPC-157 from TB-500?
BPC-157 primarily acts through angiogenesis (VEGFR2 pathway), growth factor modulation, and nitric oxide system interactions with predominantly local effects at the injury site. TB-500 regulates actin dynamics and cell migration with more pronounced systemic activity throughout the body. The mechanisms are complementary rather than overlapping, which is why combination research is common.
What is the relationship between BPC-157 and Body Protection Compound?
BPC-157 is the specific 15-amino acid fragment of the larger Body Protection Compound that demonstrates biological activity. The full protein from which it derives is found in human gastric juice. BPC-157 is also referred to as Pentadecapeptide BPC 157 ("pentadecapeptide" meaning 15 amino acids) or Bepecin in research literature.
What are the storage requirements for BPC-157?
Lyophilised (powder) form: stable at room temperature short-term; refrigeration (2-8°C) or freezing (-20°C) recommended for long-term storage of 12+ months. Reconstituted solution: refrigeration required (2-8°C), stable for 4-6 weeks. Do not freeze reconstituted solution.
What is the molecular weight of BPC-157?
BPC-157 has a molecular weight of 1419.53 g/mol (Daltons).
Can BPC-157 help with gut issues?
BPC-157 has been extensively studied for gastrointestinal applications given its origin from gastric juice. Research has examined its effects on gastric ulcers, NSAID-induced gastropathy, inflammatory bowel disease models, intestinal permeability (leaky gut), oesophageal damage, and surgical anastomosis healing. The peptide demonstrates protective and healing effects across multiple GI conditions in published research.
The Science: How BPC-157 Works
Mechanism of Action
BPC-157 exerts its effects through multiple interconnected pathways, which explains the broad tissue activity observed across different research models. Rather than acting through a single receptor, BPC-157 appears to modulate several fundamental repair processes.
VEGFR2 and Angiogenesis
The primary mechanism underlying BPC-157's healing effects involves vascular endothelial growth factor receptor 2 (VEGFR2):
- BPC-157 significantly upregulates VEGFR2 expression in injured tissues
- This promotes angiogenesis – the formation of new blood vessels from existing vasculature
- Increased vascularisation delivers oxygen, nutrients, and repair cells to damaged tissue
- New blood vessel formation is critical for healing tissues that normally have poor blood supply (tendons, ligaments)
Nitric Oxide System Modulation
BPC-157 demonstrates complex, modulatory interactions with the nitric oxide (NO) system:
- Upregulates endothelial nitric oxide synthase (eNOS) expression, promoting beneficial vascular effects
- Modulates inducible nitric oxide synthase (iNOS) activity, reducing excessive inflammatory NO production
- Through NO modulation, affects blood vessel dilation, blood flow, and vascular permeability
Growth Factor Modulation
Research demonstrates BPC-157 affects the expression and activity of multiple growth factors involved in tissue repair:
- EGF (Epidermal Growth Factor): Enhanced epithelial regeneration and wound coverage
- FGF (Fibroblast Growth Factor): Increased fibroblast proliferation and collagen synthesis
- TGF-β (Transforming Growth Factor Beta): Modulated tissue remodelling responses
- NGF (Nerve Growth Factor): Supported nerve tissue regeneration and neuroprotection
- VEGF (Vascular Endothelial Growth Factor): Angiogenesis promotion
Amino Acid Sequence and Structure
Full Sequence (Three-Letter Code): Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Single-Letter Code: GEPPPGKPADDAGLV
Structural Features
The triple-proline motif (Pro-Pro-Pro) at positions 3-5 is the key structural feature:
- Creates a rigid, kinked structure (polyproline II helix)
- Confers exceptional resistance to enzymatic degradation
- Provides stability in acidic conditions
- Enables oral administration for gastrointestinal research applications
Technical Specifications
| Systematic Name | Pentadecapeptide BPC 157 |
|---|---|
| Other Names | Body Protection Compound-157, Bepecin, PL 14736 |
| Amino Acid Count | 15 |
| Sequence | GEPPPGKPADDAGLV |
| Molecular Formula | C62H98N16O22 |
| Molecular Weight | 1419.53 g/mol |
| CAS Number | 137525-51-0 |
| Isoelectric Point | ~4.2 |
| Net Charge (pH 7) | -2 |
| Appearance | White to off-white lyophilised powder |
| Solubility | Freely soluble in water and aqueous buffers |
| Purity (PurposeLabs) | ≥99% (HPLC verified) |
| Storage (Lyophilised) | -20°C long-term, 2-8°C short-term |
| Storage (Reconstituted) | 2-8°C, use within 4-6 weeks |
Quality: Australian University Testing
Why Peptide Quality Matters
The research peptide market contains products of highly variable quality. Independent testing of products from various suppliers has revealed significant issues:
- Purity levels as low as 50% in products claiming "99% purity"
- Incorrect amino acid sequences (entirely wrong peptides)
- Truncated sequences (missing amino acids)
- Bacterial endotoxin contamination
- Oxidised or degraded peptides with reduced activity
Our Testing Protocol
Every batch of BPC-157 from PurposeLabs undergoes comprehensive testing at a leading proteomics laboratory based at an Australian university in Sydney – one of Australia's premier analytical facilities.
Confirms purity levels of ≥99%, identifies any impurities or degradation products.
Verifies exact molecular weight, confirms correct amino acid sequence.
Determines actual peptide content versus salt, moisture, and counter-ions.
Why Australian University Testing?
Our testing partner is an established, verifiable proteomics facility at a major Australian university, with published research credentials, transparent methodology, and no commercial conflict of interest. This contrasts with overseas "certificates of analysis" from unknown or unverifiable laboratories.
Shop BPC-157
Australian university tested. 99%+ purity verified by HPLC and mass spectrometry. Fast shipping from Sydney.
| Product | Size | Price |
|---|
References
Key studies for researchers seeking primary literature:
- Sikiric P, et al. "Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions." European Journal of Pharmacology, 1999.
- Staresinic M, et al. "Beneficial effect of BPC 157 on ischemicreperfusion injury in the rat." Journal of Physiology and Pharmacology, 2003.
- Pevec D, et al. "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Medical Science Monitor, 2010.
- Sikiric P, et al. "Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications." Current Neuropharmacology, 2016.
- Seiwerth S, et al. "BPC 157's effect on healing." Journal of Physiology Paris, 2018.
- Kang EA, et al. "Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts." Molecules, 2019.
- Hsieh MJ, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." Journal of Molecular Medicine, 2017.
- Tkalcevic VI, et al. "Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression." European Journal of Pharmacology, 2007.
- Cesarec V, et al. "Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy." European Journal of Pharmacology, 2013.
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design, 2011.
Disclaimer
All products sold by PurposeLabs are intended for laboratory and research use only. They are not intended for human or animal consumption. The information provided is for educational purposes only and should not be construed as medical advice. Consult with qualified healthcare professionals for any health-related decisions.
BPC-157 is not approved by the TGA for therapeutic use in Australia. Products are sold strictly for research purposes in accordance with Australian regulations.